Department of Chemistry, University of Minnesota-Twin Cities, 207 Pleasant St. SE, Minneapolis, MN, 55455, USA.
Department of Medicinal Chemistry, University of Minnesota-Twin Cities, 2231 6th St. SE, Minneapolis, MN, 55455, USA.
Angew Chem Int Ed Engl. 2021 Jan 18;60(3):1220-1226. doi: 10.1002/anie.202008625. Epub 2020 Nov 18.
Bromodomain and extra-terminal (BET) family proteins, BRD2-4 and T, are important drug targets; however, the biological functions of each bromodomain remain ill-defined. Chemical probes that selectively inhibit a single BET bromodomain are lacking, although pan inhibitors of the first (D1), and second (D2), bromodomain are known. Here, we develop selective BET D1 inhibitors with preferred binding to BRD4 D1. In competitive inhibition assays, we show that our lead compound is 9-33 fold selective for BRD4 D1 over the other BET bromodomains. X-ray crystallography supports a role for the selectivity based on reorganization of a non-conserved lysine and displacement of an additional structured water in the BRD4 D1 binding site relative to our prior lead. Whereas pan-D1 inhibitors displace BRD4 from MYC enhancers, BRD4 D1 inhibition in MM.1S cells is insufficient for stopping Myc expression and may lead to its upregulation. Future analysis of BRD4 D1 gene regulation may shed light on differential BET bromodomain functions.
溴结构域和末端(BET)家族蛋白,BRD2-4 和 T,是重要的药物靶点;然而,每个溴结构域的生物学功能仍未确定。尽管已经有针对第一(D1)和第二(D2)溴结构域的泛 BET 抑制剂,但缺乏选择性抑制单个 BET 溴结构域的化学探针。在这里,我们开发了选择性 BET D1 抑制剂,优先与 BRD4 D1 结合。在竞争性抑制测定中,我们表明我们的先导化合物对 BRD4 D1 的选择性是其他 BET 溴结构域的 9-33 倍。X 射线晶体学支持基于非保守赖氨酸的重排和 BRD4 D1 结合位点中额外结构水的置换的选择性作用,与我们之前的先导化合物相比。虽然泛 D1 抑制剂可将 BRD4 从 MYC 增强子中置换出来,但在 MM.1S 细胞中抑制 BRD4 D1 不足以阻止 Myc 表达,并且可能导致其上调。对 BRD4 D1 基因调控的进一步分析可能阐明 BET 溴结构域功能的差异。